Array BioPharma

Array BioPharma

Array BioPharma was a biopharmaceutical company focused on the discovery, development, and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other high-burden diseases. The company was founded in 1998 and was headquartered in Boulder, Colorado. Array BioPharma was known for its innovative approach to drug discovery and development, leveraging its expertise in chemistry and biology to create a robust pipeline of therapeutic candidates.

History

Array BioPharma was established by a group of scientists with a vision to create a company that could efficiently discover and develop new drugs. Over the years, the company formed numerous partnerships with major pharmaceutical companies to advance its drug candidates. In 2019, Array BioPharma was acquired by Pfizer, a global pharmaceutical giant, for approximately $11.4 billion.

Research and Development

Array BioPharma's research and development efforts were primarily focused on oncology. The company utilized a proprietary drug discovery platform that integrated chemistry and biology to identify promising drug candidates. This platform enabled Array to rapidly advance compounds from discovery through clinical development.

Key Products

Array BioPharma developed several notable drugs, including:

• Braftovi (encorafenib): A BRAF inhibitor used in combination with Mektovi (binimetinib) for the treatment of patients with BRAF-mutant melanoma.
• Mektovi (binimetinib): A MEK inhibitor used in combination with Braftovi for the treatment of BRAF-mutant melanoma.

These drugs were approved by the U.S. Food and Drug Administration (FDA) and other regulatory agencies worldwide, providing new treatment options for patients with specific types of cancer.

Collaborations and Partnerships

Array BioPharma engaged in numerous collaborations with other pharmaceutical companies to enhance its drug development capabilities. These partnerships allowed Array to leverage external expertise and resources, accelerating the development of its drug candidates.

Acquisition by Pfizer

In June 2019, Pfizer announced its acquisition of Array BioPharma for $48 per share in cash, totaling approximately $11.4 billion. This acquisition was part of Pfizer's strategy to expand its oncology portfolio and strengthen its position in the cancer treatment market.

Legacy

Array BioPharma's legacy lies in its contribution to the field of targeted cancer therapies. The company's innovative approach to drug discovery and development has had a lasting impact on the treatment of cancer, providing new hope for patients with difficult-to-treat malignancies.

Also see

• Pfizer
• Oncology
• Targeted therapy
• Drug discovery
• Biopharmaceutical